Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb's product portfolio includes several key offerings that contribute to its market position. The company's dry eye disease (DED) prescription drugs, particularly Miebo and Xiidra ...

Bausch + Lomb's product portfolio includes several key offerings that contribute to its market position. The company's dry eye disease (DED) prescription drugs, particularly Miebo and Xiidra, have ...

Detailed price information for Bausch Health Companies Inc (BHC-N) from The Globe and Mail including charting and trades.

Bausch + Lomb was put up for sale after a planned separation ... from sales of contact lenses and dry eye drugs Xiidra and Miebo. The company also sells surgical equipment to ophthalmologists.

Once that is accomplished, perfluorohexyloctane (Miebo, Bausch + Lomb) drops can be helpful. Although these are drops, they are preservative-free, non-irritating and can help protect the tear film ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...